Replies to post #2035 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Is ENTA the odds on favorite in the [HBV] inhibitor space…?

In the all-oral arena, ENTA is the only participant of any consequence.

…do you see some possible synergy with T-cell approaches resulting in combos there?

There could be synergy, but ENTA is committed to seeking an all-oral functional cure, which makes a lot of sense from a business standpoint.